Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome
Background: Irritable bowel syndrome (IBS) is a stress-sensitive disorder of brain-gut interactions associated with a higher prevalence of early adverse life events (EALs). However, it is incompletely understood how trauma severity or disclosure influence the risk of developing IBS or symptom severity. Aims: To determine whether (1) IBS patients report a greater number of EALs compared with healthy controls; (2) trauma severity and first age of EAL increase the odds of IBS; (3) confiding in others reduces the odds of IBS; (4) the number, trauma severity, and first age of EAL are associated with symptom severity; (5) sex differences exist. Methods: In total, 197 IBS patients (72% women, mean age=30.28 y) and 165 healthy controls (59% women, mean age=30.77 y) completed the Childhood Traumatic Events Scale, measuring severity of EALs and degree of confiding in others. Regression analyses were used to predict IBS status from EALs and association between gastrointestinal symptoms and EALs. Results: A greater number of EALs [odds ratio (OR)=1.36, 95% confidence interval (CI), 1.14-1.62; P
CONCLUSION: MiR-510 downregulation in intestinal tissue might contribute to PI-IBS via targeting PRDX1. The results of this study will not only enrich the pathogenesis of PI-IBS but also make us understand the biological activity of miR-510 and provide important experimental basis for PI-IBS clinical treatment targeting miR-510. PMID: 31934286 [PubMed]
Patients in GP surgeries in Bristol are being invited to take part in a large trial of low-dose amitriptyline for irritable bowel syndrome (IBS) lead by researchers from the universities of Bristol, Leeds and Southampton.
Conclusions: Stool microbial diversity and composition are linked to daily extraintestinal symptoms, stool consistency, and QOL in women with IBS.
In the absence of a well-established therapeutic approach, patients with irritable bowel syndrome seek alternative strategies such as probiotics.
Publication date: 9 January 2020Source: Cell, Volume 180, Issue 1Author(s): Fanny Matheis, Paul A. Muller, Christina L. Graves, Ilana Gabanyi, Zachary J. Kerner, Diego Costa-Borges, Tomasz Ahrends, Philip Rosenstiel, Daniel MucidaSummaryEnteric-associated neurons (EANs) are closely associated with immune cells and continuously monitor and modulate homeostatic intestinal functions, including motility and nutrient sensing. Bidirectional interactions between neuronal and immune cells are altered during disease processes such as neurodegeneration or irritable bowel syndrome. We investigated the effects of infection-induced inf...
Conclusions: Phloroglucinol could be a safe and beneficial option for the management of overall IBS symptoms in patients with IBS-D. Further large scaled studies are warranted. PMID: 31917916 [PubMed]
Authors: Steinsvik EK, Valeur J, Hausken T, Gilja OH Abstract Background/Aims: Dyspeptic symptoms are common in patients with functional gastrointestinal (GI) disorders, and may be related to visceral hypersensitivity. We aim to explore the relation between visceral hypersensitivity by using an ultrasonographic meal test and questionnaires in patients with irritable bowel syndrome (IBS) and/or functional dyspepsia (FD). Methods: Patients (FD, n = 94; IBS, n = 88; IBS + FD, n = 66, healthy controls [HC], n = 30) were recruited consecutively and examined with ultrasound of the proximal and distal stomach after dr...
Authors: Lee HS PMID: 31917911 [PubMed]
(Rockefeller University) For some unlucky people, a bout of intestinal distress like traveler's diarrhea leads to irritable bowel syndrome. Recent discoveries have given scientists a better idea of how this happens, and potential leads for new treatments.
Traditional treatments for irritable bowel syndrome (IBS) are supported only by limited data from trials with significant risk of bias, according to a systematic review and network meta-analysis.Reuters Health Information